Research programme: antibody-drug conjugates - ImmunoGen

Drug Profile

Research programme: antibody-drug conjugates - ImmunoGen

Alternative Names: Anti-ADAM9 antibody-drug conjugates; Anti-c-Met-DGN 549; Anti-c-Met-DM4; anti-CD123 ADC - Immunogen; Anti-CD33-3m; Anti-CD56-3m; Anti-cMet antibody-drug conjugate; Anti-EGFR-3m; Anti-FRα-3m; CD19-targeting antibody-drug conjugate; huB4-DGN462; hucMet-DM4; hucMet27-DGN 549; IGN P1; IGNs-ADCs; M-DGN549; M9346A NL DM

Latest Information Update: 05 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImmunoGen
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies; Small molecules
  • Mechanism of Action ADAM9 protein modulators; Alkylating agents; CD19 antigen inhibitors; CD33 antigen inhibitors; CD56 antigen inhibitors; DNA cross linking agents; Epidermal growth factor receptor antagonists; Folate receptor 1 antagonists; Proto oncogene protein c met inhibitors; Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 05 Jun 2018 Antibody drug conjugates are still in preclinical development for Solid Tumours in USA (Parenteral)
  • 04 May 2018 Immunogen plans IND-enabling activities trial before year end
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top